.@DrKushalani, of @MoffittNews, previews the primary analysis of the randomized phase 3 HBI-8000-303 trial, evaluating nivolumab plus HBI-8000 or placebo in advanced melanoma #mels

OncLive.com· @OncLive · X·2026-10-24 20:29· 16 小时前评分45

正文 · 机器翻译

.@DrKushalani（来自 @MoffittNews）预览了随机 III 期 HBI-8000-303 试验的主要分析，该试验评估 nivolumab 联合 HBI-8000 或安慰剂治疗晚期黑色素瘤 #melsm #ESMO26 @myESMO

243 浏览 · 2 赞 · 0 转发 · 0 回复

会议摘要

2081PNCT04949113 NCT04949113 NCT04949113按 Melanoma 对上

Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity

https://esmocongress.esmo.org

4736O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上

Results from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)

https://esmocongress.esmo.org

4757RO按 Rapid oral 1: Genitourinary tumours, renal and urothelial 对上

Final pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)

https://esmocongress.esmo.org

LBA54按 Proffered paper: Melanoma and other skin tumours 对上

Primary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma

https://esmocongress.esmo.org

NCT04884282NCT04884282按 - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) 对上

- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

https://esmocongress.esmo.org

来源：OncLive.com · x.com